SUMMARY The superoxide (02-) production of stimulated polymorphonuclear leucocytes is increased in patients with rheumatoid arthritis and osteoarthritis compared with controls. Treatment of these different groups with pharmacological amounts of the non-steroidal antiinflammatory drug piroxicam in vivo resulted in a decrease of about 25% in 02 secretion by isolated granulocytes. In vitro experiments showed that piroxicam inhibits 02 production of granulocytes by interference with the stimulation of the NADPH-oxidase. Piroxicam caused diminished 02 production of membrane fragments if it was present during the stimulation of the NADPH-oxidase of the intact cells. During the actual 02 production of the stimulated membrane fragments piroxicam had no effect. It is concluded that piroxicam is able to inhibit granulocyte 02 production by blocking the activation of NADPH-oxidase, which results in diminished tissue destruction by oxygen free radicals in inflammatory diseases.
of NSAIDs, granulocyte membrane fragments, NADPH-oxidase is inactive. When the cell is stimulated to phagocytose an activation mechanism for NADPH-oxidase is triggered. Little is known about the molecular basis of this activation mechanism. These activated oxygen intermediates together with secondary formed radicals, like the hydroxyl radical (OH'), are able to destroy membrane lipids, proteins, deoxyribonucleic acid, hyaluronic acid, and cartilage. 6 7 Previous investigations have shown that different antirheumatic drugs are able to inhibit the production of oxygen free radicals. 10 Thus it is reasonable to believe that non-steroidal anti-inflammatory drugs (NSAIDs) have a beneficial effect not only by the inhibition of cyclooxygenase, as shown by the excellent work of Vane, 11 but also by preventing the formation of oxygen free radicals. 249 Until now the inhibition of the O2 producing NADPH oxidase by NSAIDs has been mostly tested in vitro. This study is focused on the in vivo inhibition of 02 production from PMN by piroxicam, which was chosen because of the encouraging results already obtained. 12-14 02-production of PMN was tested before and at different times after the administration of piroxicam to patients with RA and osteoarthritis, and to controls. Attention was also given to the molecular level at which piroxicam interferes with the NADPH-oxidase. The RA patients (n=5) (Fig. 3) showed similar results. Again piroxicam treatment induced a significant decrease in 02 production between four and 28 hours, which was followed by a return to the basal 02 production at 48 hours.
Patients with osteoarthritis (n=7) (Fig. 4) The present investigations show that after stimulation with serum treated zymosan PMN from patients with RA or osteoarthritis produce an increased amount of 02 compared with controls. With PMA stimulated PMN the increase was only significant in the osteoarthritis group. This increased potency of PMN to produce 02 together with the availability of B stimulating factors for PMN in serum and synovial / fluid of RA patients20' will result in considerable 2-production in vivo. In the presence of non-protein bound iron, possibly derived from ferritin,2' formation of the very toxic hydroxyl radical has to be expected, and tissue destruction will result.
The discovery of the inhibition of prostaglandin synthesis by NSAIDs, due to inhibition of cyclo- To obtain information about the mechanism of inhibition investigations were performed on the level at which piroxicam inhibited the 02 production of PMN. Isolated membrane fragments were used, which are known to contain the O2 producing NADPH-oxidase. Stimulation of the NADPH-oxidase is only possible in intact cells, possibly with the exception of stimulation with cis unsaturated fatty acids.23 For this reason cells were homogenised after stimulation of the NADPHoxidase with PMA, followed by isolation of the membrane fragments. The O2 production of the PMA stimulated NADPH-oxidase of membrane fragments decreased if piroxicam was present during the activation of the NADPH-oxidase in the intact cells. Addition of piroxicam to the isolated membrane fragments had no effect on the O2 production. It can therefore be concluded that piroxicam interferes in the mechanism by which the NADPH-oxidase is activated. For this reason piroxicam can potentially be very useful for investigations designed to elucidate the mechanism by which NADPH-oxidase is stimulated.
Overall it seems reasonable to believe that piroxicam, and possibly other NSAIDs, cause improvement in RA and osteoarthritis not only by inhibition of prostaglandin synthesis but also by decrease of the O2 production of PMN and macrophages, which results in the prevention of tissue destruction caused by oxygen free radicals.
